Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
11 evidence topics · 11 sources
Summary: response by prior advanced therapy exposure
In the pooled ABTECT induction trials, 47.3% of participants had a prior inadequate response to an advanced therapy (AT-IR). The placebo-adjusted difference in clinical remission at week 8 with obefazimod 50 mg was 10.1% in participants with AT-IR and 22.4% in those without; with 25 mg, the difference was lower than with 50 mg in participants with AT-IR, and the two doses performed similarly in participants without AT-IR. In participants with prior JAK inhibitor failure, the pooled placebo-adjusted difference in clinical response with 50 mg was 34%. In the maintenance trial, clinical remission at Week 52 occurred in 72 of 117 (25 mg) and 62 of 105 (50 mg) participants against 15 of 120 with placebo among AT-IR-naive participants, and in 26 of 76 and 38 of 90 against 5 of 72 among participants with prior AT-IR. In the phase 2b open-label maintenance study, clinical remission at week 96 was 63.8% in participants naive to biologics or JAK inhibitors, and 38.8% of those with prior inadequate response were in clinical remission at both weeks 48 and 96. The same direction of effect is reported for comparators: the ACG 2025 guideline states that patients have higher response and remission rates with their first therapies than after failure of other advanced therapies, and the AGA 2024 guideline places different agents in its higher-efficacy tier for advanced therapy-naive and -exposed patients. In a 2026 network meta-analysis of induction trials, obefazimod and upadacitinib showed the highest efficacy in AT-naive patients, and upadacitinib, ustekinumab, and tofacitinib ranked highest in AT-experienced patients. All obefazimod subgroup p-values are nominal.
Obefazimod induction: efficacy with and without prior inadequate response to advanced therapy
“Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In ABTECT‐1, ABTECT‐2, and pooled, a higher proportion of the AT‐IR‐Yes subgroup receiving Obe‐50 achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 12.7%, p = 0.0039; ABTECT‐2 7.6%, p = 0.0652, pooled 10.1%, p = 0.0009).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AT‐IR‐Yes subgroup, the difference from PBO across all efficacy measures was lower for pts receiving Obe‐25 relative to Obe‐50 (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AT‐IR‐No subgroup, larger proportions achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 25.0%, p < 0.0001; ABTECT‐2 19.4%, p = 0.0004; pooled 22.4%, p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the subset of pts who failed JAKi, higher proportion of pts receiving Obe‐50 or Obe‐25 achieved clinical response versus PBO. The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obefazimod induction: prior Janus kinase inhibitor failure and number of prior advanced therapies
Obefazimod maintenance: efficacy with and without prior inadequate response to advanced therapy
Obefazimod phase 2b open-label maintenance: participants naive to or refractory to biologics or JAK inhibitors
“Among the 98 patients with inadequate response to biologics (anti-TNFα, vedolizumab, ustekinumab) or JAK inhibitors, 74/98 (75.5%) achieved clinical response at week 48 and 66/98 (67.3%) at week 96; 38/98 patients (38.8%) were in clinical remission at both weeks 48 and 96 (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this subset, clinical remission was achieved by 81/119 patients (68.1%) at week 48 and by 76/119 patients (63.8%) at week 96; 89/119 (74.8%) and 82/119 patients (68.9%) had endoscopic improvement, and 54/119 (45.4%) and 58/119 patients (48.7%) achieved endoscopic remission at weeks 48 and 96, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rates of clinical remission, endoscopic improvement, and endoscopic remission at weeks 48 and 96 were numerically higher, from 25% to 33%, in the subgroup of naïve relative to refractory patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obefazimod long-term extension after dose reduction to 25 mg, by prior advanced therapy
Network meta-analysis including obefazimod, stratified by prior advanced therapy
“Analyses were stratified by prior exposure to ATs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In AT-naïve patients, obefazimod and upadacitinib showed the highest efficacy, whereas in AT-experienced patients, upadacitinib, ustekinumab, and tofacitinib ranked highest.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator rankings in biologic-exposed patients: network meta-analyses
“Overall, upadacitinib (P-score 0.93), tofacitinib (P-score 0.88), and ustekinumab (P-score 0.87) ranked highest in inducing remission in biologic-exposed patients with moderate-to-severely active UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the biologic/Janus kinase inhibitor (JAKi)-naïve population, induction studies showed similar clinical response and remission rates across most interventions, with upadacitinib demonstrating significant improvements versus most other interventions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline efficacy tiers by prior advanced therapy exposure: AGA 2024
“In adult outpatients with moderate-to-severe UC who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib*, risankizumab, guselkumab) OR an INTERMEDIATE efficacy medication (golimumab, ustekinumab, tofacitinib*, filgotinib*, mirikizumab), rather than a LOWER efficacy medication (adalimumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adult outpatients with moderate-to-severe UC who have previously been exposed to one or more advanced therapies, particularly TNF antagonists, the AGA suggests using a HIGHER efficacy medication (tofacitinib, upadacitinib, ustekinumab) OR an INTERMEDIATE efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a LOWER efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Phase 3 randomized trial of ozanimod against placebo, ozanimod was significantly more effective than placebo in achieving clinical remission with rates of 23% (vs 7%) and 17% (vs. 8%) in biologic-naïve and single biologic-exposed patients. In contrast, in patients who had been on ≥2 biologics previously, ozanimod was no more effective than placebo (4% vs. 3%) in inducing clinical remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote